Olivia Vizier

Immunomedics has developed an ADC called sacituzumab govitecan, which directly delivers chemotherapy SN-38 to TNBC tumours, which highly express Trop-2 and represents an unmet need within a highly treated cancer type. The company’s chief commercial officer Brendan Delaney explains the drug’s efficacious mechanism of action in this tumour type, as well as noting its success

Updated interim data for Adverum’s intravitreal wet age-related macular degeneration gene therapy bolstered the company’s case that the product could compete with less convenient subretinal gene therapies for the indication.

Warren Huff, Reata’s president and CEO, discussed the clinical progress of omaveloxolone and bardoxolone, as well as the company’s approach to drug development, before the stock surge in an exclusive interview with GEN Edge during the recent J.P. Morgan conference in San Francisco . . .

Dr. Lawrence Blatt, CEO, Aligos Therapeutics, discusses his company’s research around antisense oligonucleotides as potential therapies for chronic hepatitis B and other diseases of the liver. Despite an available vaccine, the incidence of chronic hepatitis B (HBV) remains high — the largest prevalence of any chronic virus that causes morbidity and mortality — in some

Thorsten Stafforst found his big break at the worst possible time. In 2012, his team at the University of Tübingen in Germany discovered that by linking enzymes to engineered strands of RNA, they could change the sequences of messenger RNA molecules in cells. In essence, they could rewrite the genome’s instructions en route to making

Awareness days and months occur throughout the calendar year to generate a greater understanding about various diseases and help increase visibility about the unmet needs related to these conditions. For many advocacy groups, these activities drive awareness and highlight rare disease states or disorders with great unmet needs.

Dean Scott could hardly see two years ago, but the Spirit River, Alta., carpenter says an experimental drug helped him regain some of his vision and added colour to his life. Scott, 45, first noticed problems with his eyes when he was a child and lost his peripheral vision.

In August of last year, Alkahest reported the results from a six-month trial that saw 40 patients with mild to moderate Alzheimer’s disease infused with a proprietary human plasma “fraction”. It appeared to arrest their expected mental decline.

Frustrated with the slow pace of drug discovery and desperate to help their loved ones, untrained family members take the work into their own hands by starting biopharma companies. But few such companies have been successful.

Valneva’s vaccine, VLA15, encourages the body’s immune system to make antibodies to defend against the bacteria that cause Lyme disease. The FDA gave VLA15 fast-track designation in 2017, and the vaccine is currently in Phase 2 clinical studies.

In drug development, assets are often aimed at a specific disease target or pathway, similar to a bullet fired from a gun. The idea of going after one precise target though, may not be the best solution for treating the totality of diseases, though.

Immunomedics, based in Morris Plains, New Jersey, is a bit of a peculiarity in the biopharma industry. Notably, it was founded in 1982, almost forty years ago, and doesn’t have a commercial product on the market. But that appears likely to soon change.

Krystal Biotech is confident enough about its pipeline of candidates of gene therapies for treating skin diseases that has started work on a new commercial manufacturing facility. It has even given it a name.

OncoCyte president and CEO Ron (Ronnie) Andrews discussed the company’s recent acquisitions and expansion of its diagnostics menu with GEN Edge . . .

Physician, scientist and investor Patrick Soon-Shiong might be considered a “square peg in a round hole,” he admits. But the Abraxane inventor’s work to enlist natural killer, dendritic and T cells in what he calls a “triangle offense” against cancer is finally coalescing, he recently told BioWorld.

Horizon 2020, the European Union’s research and innovation programme, is entering its final year. But how has the money been used to drive pharma developments in the region? We round up the most successful and innovative projects to emerge from scheme.

This week the publishing of data on Cue Biopharma’s star immunotherapy molecule, Cue 101, revealed just how much reality there is to concept. A paper published in Clinical Cancer Research on Tuesday showed research demonstrating the ability of a biologic immunotherapy drug candidate named CUE-101 to activate tumor antigen-specific antitumor immunity.

Gene therapy developer Krystal Biotech (NASDAQ: KRYS) has appointed Jennifer Chien to the newly created role of chief commercial officer. She comes to Pittsburgh-based Krystal from the Genzyme unit of Sanofi (NYSE: SNY), where she was vice president and head of genetic diseases.

Venture capitalists are betting $20 million that technology from Immuneering Corp. will enable it to develop medicines aimed at molecular targets that have long tantalized and eluded drugmakers.

If 2019 was a breakthrough year for Watertown, Mass.-based SQZ Biotech, 2020 could be a defining year as the company tests is first antigen-presenting cell asset in the clinic to treat solid tumors that are HPV positive.

“Successful drugs targeting the Wnt pathway haven’t been developed yet because the Wnt pathway is so essential to all cells,” commented Yusuf Yazici, MD, Chief Medical Officer of Samumed. “Previous drugs in development have shown many off-target effects at effective doses, rendering them unsafe for use.”

Two decades passed between the discovery of RNA interference, a natural mechanism of gene control, and approval of the first drug built on the Nobel Prize-winning science.

Some biopharmaceutical enterprises are even specializing in specific mechanisms of action by targeting and modifying RNA through temporary and ongoing treatment to avoid safety concerns that may arise from permanent gene therapy alterations. In this article, Daniel de Boer, CEO at ProQR Therapeutics, will discuss how they are advancing RNA therapies in retinal disorders.

Aligos Therapeutics Inc., a startup headed by entrepreneurs who led venture-backed Alios BioPharma Inc. to a $1.75 billion merger with Johnson & Johnson in 2014, has raised $125 million to develop treatments for hepatitis B and other liver diseases.